Epstein-Barr Virus Reactivation in COVID-19 Long-Haul Syndrome: Etiology, Immune Dysfunction, and Genomic Vulnerability

John Murphy, CEO, COVID-19 Long-haul Foundation I. Abstract The persistence of symptoms following acute SARS-CoV-2 infection—commonly referred to as long COVID—has emerged as a global health crisis. Among the most…[...]

Read More

Systemic Reluctance: Medical Inertia and the Pharmaceutical Industry’s Influence on Long COVID Treatment

Abstract Despite the global burden of Long COVID, the medical profession has demonstrated a striking reluctance to engage in consistent diagnosis, treatment, and research. This article explores the multifactorial roots…[...]

Read More